What CT aortogram protocol should be used for TAVR planning in a patient with prior bioprosthetic aortic valve replacement who now shows recurrent aortic stenosis on 2‑D echocardiography?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CT Aortogram Protocol for TAVR Planning in Bioprosthetic Valve Stenosis

For a patient with prior bioprosthetic aortic valve replacement now showing recurrent stenosis, perform an ECG-gated cardiac CT angiography covering the chest, abdomen, and pelvis with IV contrast using a dedicated TAVR protocol that includes both systolic and diastolic phase reconstructions to assess the bioprosthetic valve leaflets and plan valve-in-valve intervention. 1

Protocol Components

Coverage and Contrast Administration

The CT aortogram must extend from the aortic root through the iliofemoral vessels to assess both the valve anatomy and potential vascular access routes. CTA chest, abdomen, and pelvis with IV contrast is the guideline-recommended approach for comprehensive TAVR planning 1. This single acquisition provides all necessary anatomical information for procedural planning while minimizing radiation and contrast exposure compared to separate acquisitions.

ECG Gating Requirements

ECG synchronization is mandatory for valve-in-valve TAVR planning 2. The protocol must include:

  • Diastolic phase reconstruction (when aortic leaflets coapt) to evaluate for hypo-attenuated leaflet thickening (HALT) and assess the degree of leaflet thickening
  • Systolic phase reconstruction (maximal leaflet excursion) to evaluate for reduced leaflet motion and assess functional valve opening
  • Cine reconstructions throughout the R-R interval to comprehensively evaluate leaflet dynamics and identify any restriction 2

This is critical because bioprosthetic valve dysfunction may be due to thrombotic leaflet thickening, which appears as hypodense meniscoid thickening best visualized during diastole 2.

Key Measurements Required

The protocol must enable measurement of:

  1. Aortic annulus dimensions (area-derived diameter at the level of the deepest sinus)
  2. Sinus of Valsalva dimensions and coronary ostial heights (to assess risk of coronary obstruction)
  3. Sinotubular junction and ascending aorta dimensions
  4. Bioprosthetic valve internal diameter and leaflet assessment
  5. Iliofemoral vessel diameters, calcification, and tortuosity for access planning 3

Special Considerations for Bioprosthetic Valves

CT is superior to MRI for bioprosthetic valve assessment when metal struts are present 4. Most bioprosthetic valves contain metal components that create significant artifacts on MRI, making CT the preferred modality. The 2025 expert consensus specifically addresses that CT provides essential information for valve-in-valve procedures including 2:

  • Assessment of coronary artery patency and previous bypass grafts
  • Distance between posterior sternum and right ventricle (if surgical redo is considered)
  • Aortic root calcification and dimensions
  • Evaluation for iatrogenic complications from prior surgery

Contrast Optimization

Given the high prevalence of chronic kidney disease in TAVR candidates, protocols should be optimized to minimize contrast volume while maintaining diagnostic quality 5. This involves:

  • Timing the scan to peak aortic enhancement
  • Using test bolus or bolus tracking techniques
  • Adjusting contrast volume based on patient weight and renal function
  • Considering split-bolus techniques when feasible

Reporting Requirements

Use a structured reporting template that includes all measurements necessary for Heart Team decision-making 2. The report must specifically address:

  • Presence and severity of HALT (graded on 4-tier scale: ≤25%, 25-50%, 50-75%, >75% of leaflet involvement)
  • Presence of reduced leaflet motion
  • Bioprosthetic valve internal dimensions for valve-in-valve sizing
  • Coronary ostial heights relative to the bioprosthetic valve
  • Vascular access suitability (femoral vs. alternative approaches)
  • Any findings that would preclude transcatheter approach

Critical Pitfalls to Avoid

Do not use non-gated CT protocols – these cannot assess leaflet motion or identify HALT, which may be the cause of valve dysfunction and could affect procedural planning 2.

Do not rely on MRI if the bioprosthetic valve contains metal struts – significant artifacts will compromise image quality and measurements 4.

Do not limit coverage to the chest only – comprehensive assessment of iliofemoral access is essential and changes management in a significant proportion of cases 1.

Ensure reconstructions include both systolic and diastolic phases – evaluating only one phase will miss critical information about leaflet thickening versus motion restriction 2.

References

Related Questions

Can you still hear a murmur after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS)?
Can you provide articles on assessing the aortic valve for aortic stenosis?
What are the physical examination findings, diagnostic work‑up, and treatment options for aortic stenosis?
Is bisoprolol indicated for a patient with severe aortic stenosis, and if so, what is the appropriate dosing strategy?
What are the detailed differences between aortic sclerosis and aortic stenosis, including pathophysiology, diagnostic criteria, clinical presentation, and management?
Should teicoplanin be used instead of tigecycline for gram‑positive coverage in a patient already receiving meropenem?
What are the landmark multiple myeloma trials, presented chronologically, with detailed schedules, regimens, and dosing information?
Is there a drug interaction between cetirizine and aspirin?
What is the recommended dosing, contraindications, and monitoring for the Stonehenge Health Dynamic Calm supplement in adults seeking daily stress and mood support?
Can lettuce lower blood pressure?
Do antiemetics such as ondansetron (5‑HT3 receptor antagonist) treat nausea, vomiting, or both, and which effect is primary; and is it effective for motion‑sickness‑related and gastritis‑related symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.